Tae Hoon Lee; Byung-Hee Kang; Hak Jae Kim; Hong-Gyun Wu; Joo Ho Lee

doi:10.4143/crt.2022.1538

Articles

Page Path: HOME > Cancer Res Treat > Volume 55(3); 2023 > Article

Original Article Lung and Thoracic cancer Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non–Small Cell Lung Cancer: Tae Hoon Lee¹, Byung-Hee Kang², Hak Jae Kim^1,3, Hong-Gyun Wu^1,3, Joo Ho Lee^1,3; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2023;55(3):865-874.
DOI: https://doi.org/10.4143/crt.2022.1538
Published online: January 19, 2023

¹Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

²Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

³Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Correspondence: Joo Ho Lee, Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea,
Tel: 82-2-2072-2819, Fax: 82-2-765-3317, E-mail: jooholee@snu.ac.kr

* Tae Hoon Lee and Byung-Hee Kang contributed equally to this work.

• Received: November 22, 2022 • Accepted: January 18, 2023

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,775 Views
153 Download
3 Web of Science
3 Crossref
3 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
We investigated the clinical effects and predictive factors of severe post-chemoradiotherapy pulmonary complications (PCPC) in locally advanced non–small cell lung cancer (LA-NSCLC).
Materials and Methods
Medical records of 317 patients who underwent definitive concurrent chemoradiation (CCRT) for LA-NSCLC were reviewed retrospectively. PCPC was defined as an event of admission or emergency department visit for acute or subacute pulmonary inflammatory complications, including pneumonitis and pneumonia, within 6 months after CCRT initiation. Patient characteristics, baseline lung function tests, radiation dosimetric parameters, and laboratory tests were analyzed to investigate their association with PCPC. Prognostic endpoints were disease progression rate (DPR) and overall survival (OS).
Results
PCPC was reported in 53 patients (16.7%). The OS of patients with PCPC was significantly worse (35.0% in 2 years) than that of patients without PCPC (67.0% in 2 years, p < 0.001). However, 2-year DPRs were 77.0% and 70.7% in patients with and without PCPC, respectively, which were not significantly different (p=0.087). In multivariate logistic regression, PCPC was independently associated with grade ≥ 1 hypoalbuminemia during CCRT (odds ratio [OR], 5.670; 95% confidence interval [CI], 2.487 to 13.40; p < 0.001), lower diffusing capacity of carbon monoxide (DLCO) (per mL/min/mmHg; OR, 0.855; 95% CI, 0.743 to 0.974; p=0.022), and higher lung V5 (per 10%; OR, 1.872; 95% CI, 1.336 to 2.699; p < 0.001).
Conclusion
PCPC might be a clinical endpoint to evaluate complications and predict the survival of patients subjected to CCRT for LA-NSCLC. Hypoalbuminaemia, DLCO, and lung V5 might predict PCPC in LA-NSCLC.
Key words: Lung neoplasms, Chemoradiotherapy, Hypoalbuminaemia, Pulmonary diffusing capacity

Introduction

Lung cancer is one of the most frequently diagnosed cancers worldwide [1]. Approximately 20%–30% of newly diagnosed non–small cell lung cancer (NSCLC) cases have stage III disease [2]. For locally advanced (LA) NSCLC, concurrent chemoradiotherapy (CCRT) is the standard of care for the definitive aim. Despite recent applications of immunotherapy combinations, the prognosis of LA-NSCLC remains poor with a 40% overall survival (OS) rate over 5 years [3]. One of the factors contributing to these low survival outcomes is early treatment-related mortality; approximately 10% of patients in the PACIFIC trial died 6 months after chemoradiotherapy [4]. In the trial, pneumonia and pneumonitis were the most common severe adverse events and causes of standard treatment discontinuation [4,5].

Severe and fatal radiation pneumonitis, ranging from 3.62% to 7.85% [6], can cause severe morbidities and mortality. Previous studies were conducted to predict the occurrence of radiation pneumonitis, and most of them used symptomatic pneumonitis as an endpoint [7]. Pneumonia, another common event after CCRT, has been underestimated in studies predicting morbidities after CCRT. However, approximately 3%–4% of grade ≥ 3 pneumonia cases occurred in randomised trials [5]. Patients undergoing CCRT are susceptible to infection because chemotherapy-induced neutropenia is frequent [8]. Although they need different treatments, these two pulmonary inflammatory complications are frequently superimposed on each other and should be managed simultaneously [9]. Therefore, the clinical impact and risk conditions of pneumonia are similar to those of pneumonitis and should be assessed as one of the critical conditions after CCRT.

We hypothesized that predicting post-chemoradiotherapy pulmonary complications (PCPC), which includes pneumonitis and pneumonia, could be more clinically relevant than predicting symptomatic pneumonitis alone. This study aimed to show how PCPC could affect clinical outcomes as a possible clinical endpoint and explore variables likely to be associated with PCPC.

Materials and Methods

1. Study population and treatment

The medical records of 317 patients who underwent definitive CCRT for LA-NSCLC (inoperable stage II and stage III) from January 2012 to August 2020 were reviewed retrospectively. No minimum radiation dose requirement was set. Patients with neoadjuvant chemotherapy were excluded. All patients underwent radiation therapy encompassing the known disease extent in the thoracic area identified by computed tomography (CT) scan, positron emission tomography (PET) scan, and endobronchial ultrasound-guided transbronchial needle aspiration. The gross tumor volume (GTV) was delineated for primary tumor and nodal metastasis identified by these examinations. The clinical target volume (CTV) was created by expanding the GTV toward surrounding normal tissue to encompass microscopic tumor extension. GTV-to-CTV expansion was 7 mm for primary GTV and 5 mm for nodal GTV. The planning target volume (PTV) was constructed by expanding the CTV by 7–10 mm. Radiation dose was prescribed to the PTV. Dose-fractionation regimen was decided by treating radiation oncologist, and disease involvement, baseline lung function, and lung radiation dose was mainly considered. Sixty Gy in 30 fractions were the most frequently prescribed. Three-dimensional conformal radiation therapy (3D-CRT) and volumetric modulated arc therapy (VMAT) were used for radiation therapy planning and delivery.

Chemotherapy was administered concurrently with radiation therapy. Frequently used chemotherapeutic regimens were carboplatin-paclitaxel and docetaxel-cisplatin. For carboplatin-paclitaxel regimen, carboplatin was administered to a targeted area under the plasma concentration-time curve of 2, and paclitaxel was administered at a dose of 50 mg/m². For docetaxel-cisplatin regimen, 20 mg/m² of docetaxel and 20 mg/m² of cisplatin were administered. The patient received these chemotherapeutic agents weekly. Consolidation immunotherapy with durvalumab became available in late 2018 and was administered to some patients.

The patients were follow-up with at 1 month after the completion of CCRT. Thereafter, follow-up interval was 3 months for 2 years. For the third to fifth years, follow-up interval was 6 months. Clinical examination and chest CT scan were performed for every follow-up visit. When radiation changes in chest CT were superimposed with suspected progressive lesion, short-term follow-up CT scan was performed to identify increase of nodular lesion or solid portion of suspected recurred site. If the progression was still uncertain after follow-up CT scan, PET scan was performed to identify hypermetabolism of suspected progressive lesion.

2. Post-chemoradiotherapy pulmonary complications

PCPC was defined as admission or emergency department visit for the treatment of pulmonary inflammatory complication, which was defined as pneumonia and pneumonitis, within 6 months from the initiation of CCRT. Hospital visits for other causes, such as supportive care or treatment of oesophagitis, were excluded. The events after confirmation of disease progression were censored. The adverse events of CCRT were assessed and graded in accordance with the Common Terminology Criteria for Adverse Events ver. 5.0. Distinguishing infectious pneumonia and radiation pneumonitis was performed by a board-certified radiation oncologist. Clinical features at the presentation such as location of consolidation in chest CT scan (in-field vs. out-field), onset of adverse event, signs of infection, and identification of infectious organism was considered first. If the category of pulmonary complication was uncertain, response for corresponding treatment and clinical course were taken into account. If the classification was still inconclusive, such pulmonary adverse event was classified as superimposed and counted as both pneumonia and pneumonitis.

Several covariates, including baseline patient characteristics, results of pulmonary function tests performed at disease diagnosis, dosimetric features of radiation therapy, and results of laboratory test performed at least once per 2 weeks during CCRT, were selected to evaluate their potential association with PCPC. Twenty-eight covariates were analyzed to investigate their association with PCPC. Sex, age at diagnosis, body mass index, smoking history (pack-year), histology (others vs. adenocarcinoma), and regimen of concurrent chemotherapy were chosen from patient characteristics. The absolute value and relative percentage of the predicted value of forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), FEV₁/FVC, and diffusing capacity of carbon monoxide (DLCO) were selected from baseline pulmonary function tests. Radiation therapy technique, equivalent dose in 2 Gy fractions of the prescribed dose, bilateral lung mean dose, bilateral lung percentage volume that received more than 5 Gy (V5), bilateral lung percentage volume that received more than 20 Gy (V20), bilateral lung volume, mean heart dose, size of the PTV, and duration of radiation therapy were selected from radiation therapy-related features. The bilateral lung in the radiation plan was delineated by excluding the GTV. Anemia (grade ≥ 2), leucopenia (grade ≥ 2), neutropenia (grade ≥ 2), lymphocytopenia (grade ≥ 3), thrombocytopenia (grade ≥ 2), and hypoalbuminemia (grade ≥ 1, < 3.3 g/dL following the reference range of the institution) were selected from the laboratory tests. The grading of abnormal laboratory tests was evaluated using the nadir of each value during CCRT. The cutoff points of abnormal laboratory test results were selected considering the prevalence of each abnormality. Logistic regression analyses were performed to identify the predictors of PCPC. p-values were adjusted by controlling the false discovery rate [10]. Covariates with adjusted p-values lower than 0.1 were integrated into the multivariate logistic regression.

3. Prognostic endpoints and statistics

The prognostic endpoints in this study were the disease progression rate (DPR) and OS. A DPR event was defined as any disease progression. An OS event was defined as the death of a patient by any cause. These events were measured from the start of CCRT. A Kaplan–Meier estimator was applied to calculate the DPR and OS. A log-rank test was conducted to compare prognostic endpoints. OS events were subcategorized into ‘early death’ and ‘late death.’ Early death was defined as death that occurred within 6 months from CCRT initiation. Otherwise, events were considered late death. The crude rate of early death from all OS events was compared between patients with and without PCPC.

Pearson’s chi-square test with or without Yate’s continuity correction and Student’s t test were used to comparing categorical and continuous variables between two patient groups, respectively. Data with p < 0.05 were defined as statistically significant. All statistical analyses were conducted using R ver. 4.2.1 (The R Foundation for Statistical Computing, Vienna, Austria).

Results

1. Patient characteristics

The median follow-up period was 30 months (range, 1 to 125 months). The patients were predominantly male (84.2%) with good performance (Eastern Cooperative Oncology Group scale 0–1, 98.7%) at initial diagnosis. Most patients (79.8%) were current or ex-smokers. Similar rates of adenocarcinoma (44.5%) and squamous cell carcinoma (46.1%) were reported. More than half (54.9%) of the patients had stage IIIA disease. As concurrent chemotherapy, carboplatin and paclitaxel were administered to 71.9% of the patients, and docetaxel and cisplatin were given to 24.9% of the patients. The percentage of the patients who received VMAT was slightly higher than that of the patients who underwent 3D-CRT (52.1% vs. 47.9%). Furthermore, 23 patients (7.3%) underwent consolidative durvalumab. The patient characteristics and details of the delivered treatment in terms of the occurrence of PCPC are summarised in Table 1. Patients with PCPC were older (median, 70 years vs. 65 years), and the number of ex-smokers was higher than that of current smokers (54.7% vs. 36.7%). The percentage of patients who had PCPC and were diagnosed with stage IIIA (62.3% vs. 53.4%) and IIIC disease (15.1% vs. 7.6%) was higher. In the lung function test, the patients who experienced PCPC had a lower absolute value of FVC, absolute value of DLCO, and relative rate of DLCO. A higher rate of utilization of VMAT was observed in patients with PCPC (66.0% vs. 49.2%). The patients with PCPC had larger PTV, higher bilateral lung doses (mean, V5, V20), and heart doses.

2. Adverse events

PCPC was reported in 53 patients (16.7%). Amongst them, 18 patients (34.0%) visited hospitals due to radiation pneumonitis, and 18 cases (34.0%) were due to infectious pneumonia. The 17 remaining cases (32.1%) had pulmonary inflammation, but they could not be easily categorized into radiation pneumonitis or infectious pneumonia. These pulmonary adverse events were considered superimposed events. Furthermore, 13 patients (4.1%) died from PCPC. The adverse event grading of symptomatic radiation pneumonitis and abnormal laboratory results is summarised in Table 2. Symptomatic (grade ≥ 2) pneumonitis was presented in 85 patients (26.8%), including 22 severe (grade ≥ 3) cases (6.9%). Infectious pneumonia was reported in 43 patients (13.6%), including 30 severe cases (9.5%). The most common grade 3–4 adverse events were lymphocytopenia (82.3%), leucopenia (19.9%), and neutropenia (12.4%). Anemia, thrombocytopenia, and hypoalbuminemia were also common, but no grade ≥ 3 events amongst these cases were reported.

3. Association of post-chemoradiotherapy pulmonary complications with prognostic endpoints

The prognostic effect of PCPC on DPR and OS was investigated (Fig. 1A and B). For DPR, the 1-, 2-, and 3-year rates were 51.9%, 70.7%, and 77.1% in patients without PCPC and 64.2%, 77.0%, and 87.7% in patients with PCPC, respectively. The DPR did not significantly differ between the two groups (p=0.087). For OS, the 1-, 2-, and 3-year rates were 85.5%, 67.0%, and 55.8% in patients without PCPC and 45.2%, 35.0%, and 24.4% in patients with PCPC, respectively. The OS differed significantly between the two groups (p < 0.001). Furthermore, the effect of symptomatic (grade ≥ 2) pneumonitis on DPR and OS was investigated. The log-rank test revealed that symptomatic pneumonitis was not significantly associated with DPR (p=0.906) and OS (p=0.198) (Fig. 1C and D).

A total of 149 patients (56.4%) without PCPC died, whilst 42 patients (79.2%) with PCPC died. Furthermore, 12 early deaths (8.1%) were recorded in patients without PCPC, and 23 early deaths (54.8%) were documented in patients with PCPC. The rate of early deaths differed significantly between the two groups (p < 0.001).

4. Prediction of post-chemoradiotherapy pulmonary complications

Covariates potentially associated with PCPC were explored via univariate and multivariate logistic regression (Table 3). Univariate logistic regression showed that age at diagnosis, amount of smoking, FVC, DLCO, percentage predicted value of DLCO, radiation therapy technique, bilateral lung mean dose, bilateral lung V5, bilateral lung V20, mean heart dose, size of PTV, grade ≥ 2 anemia, grade ≥ 3 lymphocytopenia, and grade ≥ 1 hypoalbuminemia were significantly associated with PCPC. As two DLCO-related covariates and three lung dose-related covariates were selected, the percentage predicted value of DLCO, bilateral lung mean dose, and bilateral lung V20 were removed from the multivariate analysis based on p-value comparisons to avoid collinearity. Twelve covariates were incorporated into the multivariate logistic regression. DLCO (per mL/min/mmHg; odds ratio [OR], 0.855; 95% confidence interval [CI], 0.743 to 0.974; p=0.022), bilateral lung V5 (per 10%; OR, 1.872; 95% CI, 1.336 to 2.699; p < 0.001), and grade ≥ 1 hypoalbuminemia (OR, 5.670; 95% CI, 2.487 to 13.40; p < 0.001) remained as statistically significant factors in the multivariate analysis. A nomogram was constructed using these three factors (Fig. 2A). The receiver operating characteristic curve of the total points from the nomogram and occurrence of PCPC is illustrated in Fig. 2B. The area under the curve was 0.8545 (95% CI, 0.8020 to 0.9069). The calibration plot for the nomogram with bootstrapping of 100 repetitions is presented in Fig. 2C.

Discussion

This study defined PCPC as a clinically relevant endpoint of early mortality and survival outcomes. PCPC is related to poor OS but not disease control. It is also a major cause of early mortality after CCRT. Therefore, the prediction and prevention of PCPC will be clinically significant to improve survival outcomes after CCRT. Furthermore, the most common adverse events leading to the discontinuation of standard treatment are pneumonitis and pneumonia, which could affect patient survival [4]. Previous studies have attempted to predict symptomatic pneumonitis [7]. However, in the present study, PCPC was significantly associated with clinical outcomes, whereas symptomatic pneumonitis was not. Other studies have evaluated early mortality predictors, including performance status, tumor volume, lung dose, and baseline pulmonary function [11,12]. These studies have also directly examined early mortality, which is defined using the time of death; however, the current study defined PCPC to assess the effect of pulmonary inflammatory complications on early mortality. Thus, PCPC evaluation might help predict high-risk patients and prevent fatal complications.

We found that grade ≥ 1 hypoalbuminemia was strongly associated with more PCPCs. In previous studies, hypoalbuminemia was assessed to determine its effect on postoperative morbidity in various surgery types, including cancer surgery [13]. Several large surgical series investigating gastrointestinal cancers showed that hypoalbuminemia was associated with postoperative morbidity and mortality [14,15]. Furthermore, pulmonary morbidity in patients with resectable lung cancer is related to hypoalbuminemia. Li et al. [16] reported that the postoperative decrease in albumin levels after lung cancer surgery was associated with 30-day postoperative pulmonary complications. For chemoradiotherapy, Morse et al. [17] reported that hypoalbuminemia was related to radiation treatment breaks during chemoradiation in old patients with head and neck cancer. Satomi-Tsushita et al. [18] showed that more patients with hypoalbuminemia had severe benign oesophageal stricture after chemoradiation for oesophageal cancer. In a previous report, hypoalbuminemia was associated with delayed lymphopenia after CCRT for NSCLC [19]. In the current study, we concluded that hypoalbuminemia was related to PCPC for LA-NSCLC. Hypoalbuminaemia also elicited an overall prognostic effect on survival in lung cancer [20]. Notably, the current study found a detailed effect of hypoalbuminemia on pulmonary inflammatory complications, and that PCPC was implicated in early mortality and poor survival. Although Shaverdian et al. [21] reported paradoxically high albumin levels were a risk factor for treatment-related toxicities, the definition of toxicities and the extent of the disease were different from those described in the current study.

The mechanism of how hypoalbuminemia affects patient prognosis is under debate. The roles of albumin as nutritional and inflammatory markers have been discussed [22]. As a nutritional marker, serum albumin levels are included in several nutritional assessment tools [23]. Although life-threatening consequences are rare, clinically significant oesophagitis is prevalent in patients who have lung cancer and are undergoing CCRT [24]. Malnutrition can be triggered by difficulties in swallowing due to oesophagitis, and the association between serum albumin levels and PCPC may indicate a potential correlation between radiation oesophagitis and lung morbidity. Furthermore, studies have explored the role of albumin as an inflammatory biomarker. Physiological stress induces the release of pro-inflammatory cytokines and growth factors [25] that can influence hepatocytes to increase the production of acute-phase protein and decrease albumin production [26]. Tumor burden and normal tissue injury due to CCRT can be sources of physiological stress. Hypoalbuminaemia may indicate lung injury caused by cancer and treatment in patients undergoing CCRT and is associated with PCPC. However, the mechanism of how hypoalbuminemia interacts with lung morbidity needs further investigation.

The association of the baseline lung function and radiation therapy-related factors with PCPC was evaluated. In terms of pulmonary function tests, DLCO was related to PCPC in this study. Several studies have investigated the effects of FEV₁, FEV₁/FVC, and DLCO on post-chemoradiation morbidity and mortality. Similar to this study, previous reports showed that baseline DLCO was linked to pulmonary complications after CCRT [27]. Furthermore, DLCO was significantly decreased after CCRT, indicating the susceptibility of patients with low DLCO to lung injury during CCRT [28]. Although we did not show a clear association of other factors from baseline pulmonary function tests such as FEV₁ and FVC with PCPC, these other factors could not be underestimated because previous reports consistently showed the effect of FEV₁ and FVC on chemoradiation-related morbidity and mortality [11]. For dosimetric factors, we showed that bilateral lung V5 was significantly associated with PCPC. The low-dose volume of the lung might be an important factor contributing to PCPC. Some studies have described bilateral lung V20 as a well-known clinical predictor of symptomatic radiation pneumonitis [7], but others have reported that bilateral lung V5 and mean dose are also related to symptomatic radiation pneumonitis [29]. Bilateral lung V5 might contribute only to increased radiation pneumonitis amongst PCPCs. However, radiotherapy to a large body volume can cause immune suppression, including neutropenia [30] or lymphopenia [19], leading to pneumonia susceptibility. Further robust differential diagnosis methods for lung comorbidities should be used to address this issue. Nevertheless, bilateral lung V5 might be clinically relevant to predict PCPC.

This study had some limitations. As a retrospective study, it could have underreported adverse events. For example, 10 patients died early after CCRT (within 180 days after treatment), but they were not counted as PCPC cases because of follow-up loss after CCRT or definite disease progression combined with pulmonary adverse events. Univariate logistic regression was performed to select potential covariates associated with PCPC for multivariate analysis; however, this methodology has been criticized because of the possible overfitting of the constructed models. Furthermore, prediction models should be externally validated. Despite these limitations, this study provides potential risk factors of PCPC that can be easily evaluated before and throughout CCRT course.

In conclusion, we defined PCPC based on the event of admission or emergency department visit with the treatment of lung-related adverse events of CCRT. PCPC was significantly associated with survival but not disease progression. Lower baseline DLCO, higher bilateral lung V5, and grade ≥ 1 hypoalbuminemia during CCRT were associated with PCPC. This information would be clinically relevant for daily practice and further investigations.

NOTES

Ethical Statement

This study was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (IRB No. H-2003-145-1111). Informed consent was waived because of the retrospective nature of this study.

Author Contributions

Conceived and designed the analysis: Lee TH, Kang BH, Lee JH.

Collected the data: Lee TH, Kang BH.

Contributed data or analysis tools: Lee TH, Kang BH, Kim HJ, Wu HG, Lee JH.

Performed the analysis: Lee TH, Kang BH.

Wrote the paper: Lee TH, Kang BH, Lee JH.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Fig. 1

Actuarial rates of disease progression (A) and overall survival (B) in the presence of post-chemoradiotherapy pulmonary complications (PCPC), and disease progression (C) and overall survival (D) in the presence of symptomatic pneumonitis.

Fig. 2

Prediction nomogram for post-chemoradiotherapy pulmonary complications. Nomogram to predict the probability of post-chemoradiotherapy pulmonary complications (A), receiver operating characteristic curve (B), and calibration plot with bootstrapping of 100 repetitions for the nomogram (C). DLCO, diffusing capacity of carbon monoxide.

Table 1

Patient characteristics and treatment details

Characteristic	Without PCPC (n=264)	With PCPC (n=53)	p-value
Age at diagnosis (yr)	65 (40–94)	70 (48–82)	0.001
Sex
Male	43 (16.3)	7 (13.2)	0.723
Female	221 (83.7)	46 (86.8)
ECOG performance status
0–1	261 (98.9)	52 (98.1)	> 0.99
2	3 (1.1)	1 (1.9)
Smoking status
Current smoker	111 (42.0)	16 (30.2)	0.051
Ex-smoker	97 (36.7)	29 (54.7)
Non-smoker	56 (21.2)	8 (15.1)
Amount of smoking (pack-year, patients with smoking history only)	40 (1.5–120.0)	40 (10–150)	0.150
Body mass index (kg/m²)	23.34 (15.86–33.48)	23.25 (16.0–35.25)	0.757
Histology
Adenocarcinoma	119 (45.1)	22 (41.5)	0.420
Squamous cell carcinoma	118 (44.7)	28 (52.8)
Others	27 (10.2)	3 (5.7)
Clinical stage (AJCC 8th)
IIA/B	13 (4.0)	0	0.049
IIIA	141 (53.4)	33 (62.3)
IIIB	90 (34.1)	12 (22.6)
IIIC	20 (7.6)	8 (15.1)
FEV₁ (L)	2.32 (0.98–4.14)	2.17 (1.02–3.32)	0.052
FEV₁, percentage predicted value (%)	91 (36–131)	90 (51–129)	0.991
FVC (L)	3.40 (1.32–5.47)	3.22 (1.87–4.68)	0.023
FVC, percentage predicted value (%)	94 (44–129)	92 (62–127)	0.371
FEV₁/FVC, percentage predicted value (%)	70 (35–87)	70 (49–91)	0.605
DLCO (mL/min/mmHg)	15.9 (6.7–29.6)	12.5 (5.6–22.8)	< 0.001
DLCO, percentage predicted value (%)	88 (42–142)	76 (43–118)	< 0.001
Regimen of concurrent chemotherapy
Carboplatin and paclitaxel	187 (70.8)	41 (77.4)	0.720
Docetaxel and cisplatin	68 (25.8)	11 (20.8)
Weekly cisplatin	3 (1.1)	0
Others	6 (2.3)	1 (1.9)
Radiation therapy technique
3D-CRT	134 (50.8)	18 (34.0)	0.037
VMAT	130 (49.2)	35 (66.0)
Consolidative durvalumab	20 (7.6)	3 (5.7)	0.841
EQD2 of prescribed dose (Gy)	60.0 (44.0–93.3)	60.0 (40.0–81.3)	0.054
Bilateral lung mean dose (Gy)	15.76 (4.33–24.05)	18.07 (4.78–22.75)	< 0.001
Bilateral lung V5 (%)	57.7 (16.7–96.6)	72.8 (27.9–100.0)	< 0.001
Bilateral lung V20 (%)	25.5 (5.8–44.1)	32.3 (4.7–41.5)	< 0.001
Bilateral lung volume (cm³)	3,183 (1,336–5,960)	2,876 (1,699–4,680)	0.196
Heart mean dose (Gy)	10.17 (0.0–39.63)	16.89 (0.10–41.23)	< 0.001
Size of PTV (cm³)	350 (63–1,188)	413 (137–1,324)	0.026
Duration of radiation therapy (day)	44 (16–88)	44 (20–56)	0.452

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiation therapy; AJCC, American Joint Committee on Cancer; DLCO, diffusing capacity of carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EQD2, equivalent dose in 2 Gy fractions; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; PCPC, post-chemoradiotherapy pulmonary complication; PTV, planning target volume; VMAT, volumetric modulated arc therapy.

Table 2

Toxicity grading of symptomatic radiation pneumonitis and abnormal laboratory results

Grade	Symptomatic radiation pneumonitis	Pneumonia	Anemia	Leukopenia	Neutropenia	Lymphocytopenia	Thrombocytopenia	Hypoalbuminemia
1	-^a)	-^b)	215 (68.0)	90 (28.5)	37 (11.7)	5 (1.6)	78 (24.7)	33 (10.4)
2	63 (19.9)	13 (4.1)	77 (24.4)	107 (33.9)	59 (18.7)	48 (15.1)	10 (3.2)	32 (10.1)
3	10 (3.2)	16 (5.0)	0	56 (17.7)	35 (11.1)	179 (56.5)	5 (1.6)	2 (0.6)
4	3 (0.9)	4 (1.3)	0	7 (2.2)	4 (1.3)	82 (25.9)	1 (0.3)	0
5	9 (2.8)	10 (3.2)	0	-^b)	-^b)	-^b)	-^b)	0

Values are presented as number (%).

^a) Grade 1 radiation pneumonitis is asymptomatic,

^b) The event was not defined in Common Terminology Criteria for Adverse Events ver. 5.0.

Table 3

Univariate and multivariate analyses of the occurrence of post-chemoradiotherapy pulmonary complications

Characteristic (comparison vs. reference)	Univariate analysis			Multivariate analysis^a)
Characteristic (comparison vs. reference)	OR	95% CI	Adjusted p-value	OR	95% CI	p-value
Age at diagnosis (continuous, per a year)	1.050	1.015–1.088	0.019	1.007	0.959–1.056	0.790
Sex (female vs. male)	0.782	0.306–1.751	0.767	-	-	-
Amount of smoking (continuous, per pack-year)	1.013	1.001–1.026	0.083	1.010	0.992–1.028	0.248
Body mass index (continuous, per kg/m²)	0.985	0.893–1.083	0.834	-	-	-
Histology (others vs. adenocarcinoma)	1.156	0.639–2.123	0.771	-	-	-
FEV₁ (continuous, L)	0.660	0.401–1.061	0.162	-	-	-
FEV₁, percentage predicted value (continuous, per 10%)	0.999	0.862–1.160	0.994	-	-	-
FVC (continuous, per L)	0.628	0.415–0.936	0.062	0.741	0.398–1.346	0.333
FVC, percentage predicted value (continuous, per 10%)	0.916	0.757–1.110	0.545	-	-	-
FEV₁/FVC, percentage predicted value (continuous, per 10%)	1.075	0.821–1.427	0.769	-	-	-
DLCO (continuous, per mL/min/mmHg)	0.801	0.729–0.872	< 0.001	0.855	0.743–0.974	0.022
DLCO, percentage predicted value (continuous, per 10%)	0.662	0.544–0.793	< 0.001	-	-	-
Regimen of concurrent chemotherapy (others vs. carboplatin and paclitaxel)	0.711	0.341–1.388	0.523	-	-	-
Radiation therapy technique (3D-CRT vs. VMAT)	0.499	0.264–0.915	0.064	0.671	0.294–1.498	0.333
EQD2 of prescribed dose (continuous, per Gy)	0.942	0.885–0.999	0.098	0.949	0.874–1.021	0.184
Bilateral lung mean dose (continuous, per Gy)	1.178	1.081–1.293	0.001	-	-	-
Bilateral lung V5 (continuous, per 10%)	1.692	1.386–2.095	< 0.001	1.872	1.336–2.699	< 0.001
Bilateral lung V20 (continuous, per 10%)	2.358	1.548–3.705	0.001	-	-	-
Bilateral lung volume (continuous, per 100 cm³)	0.976	0.939–1.012	0.323	-	-	-
Heart mean dose (continuous, per Gy)	1.065	1.031–1.102	0.001	0.969	0.918–1.020	0.231
Size of PTV (continuous, per 100 cm³)	1.175	1.039–1.327	0.027	0.938	0.781–1.118	0.479
Duration of radiation therapy (continuous, per day)	0.981	0.934–1.030	0.630	-	-	-
Anemia grade ≥ 2 (yes vs. no)	3.084	1.645–5.754	0.001	1.357	0.575–3.135	0.478
Leukopenia grade ≥ 2 (yes vs. no)	1.002	0.552–1.830	0.994	-	-	-
Neutropenia grade ≥ 2 (yes vs. no)	1.097	0.570–2.047	0.834	-	-	-
Lymphocytopenia grade ≥ 3 (yes vs. no)	3.005	1.159–10.27	0.085	1.067	0.323–4.311	0.920
Thrombocytopenia grade ≥ 2 (yes vs. no)	0.714	0.110–2.663	0.773	-	-	-
Hypoalbuminemia grade ≥ 1 (yes vs. no)	7.186	3.806–13.77	< 0.001	5.670	2.487–13.40	< 0.001

3D-CRT, three-dimensional conformal radiation therapy; CI, confidence interval; DLCO, diffusing capacity of carbon monoxide; EQD2, equivalent dose in 2 Gy fractions; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; OR, odds ratio; PTV, planning target volume; VMAT, volumetric modulated arc therapy.

^a) Multivariate analysis was performed with data from 239 patients, due to missing data in DLCO and albumin level.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article PubMed PDF
2. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29–33. Article PubMed
3. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301–11. Article PubMed PMC
4. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–50. Article PubMed
5. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29. PubMed
6. Kuang Y, Pierce CM, Chang HC, Sosinsky AZ, Deitz AC, Keller SM, et al. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: a systematic literature review and meta-analysis. Lung Cancer. 2022;174:174–85. Article PubMed
7. Luna JM, Chao HH, Diffenderfer ES, Valdes G, Chinniah C, Ma G, et al. Predicting radiation pneumonitis in locally advanced stage II–III non-small cell lung cancer using machine learning. Radiother Oncol. 2019;133:106–12. Article PubMed
8. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer. 2008;62:356–63. Article PubMed
9. Akinosoglou KS, Karkoulias K, Marangos M. Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2013;17:8–18. PubMed
10. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol. 1995;57:289–300. Article PDF
11. Warner A, Dahele M, Hu B, Palma DA, Senan S, Oberije C, et al. Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;94:612–20. Article PubMed
12. Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016;119:495–500. Article PubMed
13. Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and clinical outcomes: what is the mechanism behind the relationship? Am Surg. 2017;83:1220–7. Article PubMed PDF
14. Lai CC, You JF, Yeh CY, Chen JS, Tang R, Wang JY, et al. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis. 2011;26:473–81. Article PubMed PDF
15. Greenblatt DY, Kelly KJ, Rajamanickam V, Wan Y, Hanson T, Rettammel R, et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol. 2011;18:2126–35. Article PubMed PDF
16. Li P, Li J, Lai Y, Wang Y, Wang X, Su J, et al. Perioperative changes of serum albumin are a predictor of postoperative pulmonary complications in lung cancer patients: a retrospective cohort study. J Thorac Dis. 2018;10:5755–63. Article PubMed PMC
17. Morse RT, Ganju RG, Gan GN, Cao Y, Neupane P, Kakarala K, et al. Sarcopenia and treatment toxicity in older adults undergoing chemoradiation for head and neck cancer: identifying factors to predict frailty. Cancers (Basel). 2022;14:2094.Article PubMed PMC
18. Satomi-Tsushita N, Honma Y, Nagashima K, Ito Y, Hirano H, Shoji H, et al. Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3 esophageal carcinoma. Anticancer Res. 2020;40:1071–7. Article PubMed
19. Kang BH, Li X, Son J, Song C, Kang HC, Kim HJ, et al. Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer. Front Oncol. 2022;12:891221.Article PubMed PMC
20. Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer. 2012;77:383–8. Article PubMed
21. Shaverdian N, Veruttipong D, Wang J, Schaue D, Kupelian P, Lee P. Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy. Clin Lung Cancer. 2016;17:39–46. Article PubMed
22. Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015;7:370–7. Article PubMed PMC
23. Keller U. Nutritional laboratory markers in malnutrition. J Clin Med. 2019;8:775.Article PubMed PMC
24. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87:690–6. Article PubMed
25. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6. Article PubMed
26. Kowalski-Saunders PW, Winwood PJ, Arthur MJ, Wright R. Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines. Hepatology. 1992;16:733–41. Article PubMed
27. Torre-Bouscoulet L, Munoz-Montano WR, Martinez-Briseno D, Lozano-Ruiz FJ, Fernandez-Plata R, Beck-Magana JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Respir Res. 2018;19:72.Article PubMed PMC PDF
28. Gopal R, Starkschall G, Tucker SL, Cox JD, Liao Z, Hanus M, et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56:114–20. Article PubMed
29. McFarlane MR, Hochstedler KA, Laucis AM, Sun Y, Chowdhury A, Matuszak MM, et al. Predictors of pneumonitis after conventionally fractionated radiotherapy for locally advanced lung cancer. Int J Radiat Oncol Biol Phys. 2021;111:1176–85. Article PubMed
30. Prabhu RS, Cassidy RJ, Landry JC. Radiation therapy and neutropenia. Curr Probl Cancer. 2015;39:292–6. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen, He Wang, Jun Dang
International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1179. CrossRef
Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities
Mark Stares, Leo R. Brown, Dhruv Abhi, Iain Phillips
Cancers.2024; 16(8): 1508. CrossRef
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Tingting Liu, Sihan Li, Silu Ding, Jingping Qiu, Chengbo Ren, Jun Chen, He Wang, Xiaoling Wang, Guang Li, Zheng He, Jun Dang
eClinicalMedicine.2023; 64: 102246. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non–Small Cell Lung Cancer

Cancer Res Treat. 2023;55(3):865-874. Published online January 19, 2023

DOI: https://doi.org/10.4143/crt.2022.1538

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non–Small Cell Lung Cancer

Fig. 1 Actuarial rates of disease progression (A) and overall survival (B) in the presence of post-chemoradiotherapy pulmonary complications (PCPC), and disease progression (C) and overall survival (D) in the presence of symptomatic pneumonitis.

Fig. 2 Prediction nomogram for post-chemoradiotherapy pulmonary complications. Nomogram to predict the probability of post-chemoradiotherapy pulmonary complications (A), receiver operating characteristic curve (B), and calibration plot with bootstrapping of 100 repetitions for the nomogram (C). DLCO, diffusing capacity of carbon monoxide.

Fig. 1

Fig. 2

Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non–Small Cell Lung Cancer

Table 1

Patient characteristics and treatment details

Characteristic	Without PCPC (n=264)	With PCPC (n=53)	p-value
Age at diagnosis (yr)	65 (40–94)	70 (48–82)	0.001
Sex
Male	43 (16.3)	7 (13.2)	0.723
Female	221 (83.7)	46 (86.8)
ECOG performance status
0–1	261 (98.9)	52 (98.1)	> 0.99
2	3 (1.1)	1 (1.9)
Smoking status
Current smoker	111 (42.0)	16 (30.2)	0.051
Ex-smoker	97 (36.7)	29 (54.7)
Non-smoker	56 (21.2)	8 (15.1)
Amount of smoking (pack-year, patients with smoking history only)	40 (1.5–120.0)	40 (10–150)	0.150
Body mass index (kg/m²)	23.34 (15.86–33.48)	23.25 (16.0–35.25)	0.757
Histology
Adenocarcinoma	119 (45.1)	22 (41.5)	0.420
Squamous cell carcinoma	118 (44.7)	28 (52.8)
Others	27 (10.2)	3 (5.7)
Clinical stage (AJCC 8th)
IIA/B	13 (4.0)	0	0.049
IIIA	141 (53.4)	33 (62.3)
IIIB	90 (34.1)	12 (22.6)
IIIC	20 (7.6)	8 (15.1)
FEV₁ (L)	2.32 (0.98–4.14)	2.17 (1.02–3.32)	0.052
FEV₁, percentage predicted value (%)	91 (36–131)	90 (51–129)	0.991
FVC (L)	3.40 (1.32–5.47)	3.22 (1.87–4.68)	0.023
FVC, percentage predicted value (%)	94 (44–129)	92 (62–127)	0.371
FEV₁/FVC, percentage predicted value (%)	70 (35–87)	70 (49–91)	0.605
DLCO (mL/min/mmHg)	15.9 (6.7–29.6)	12.5 (5.6–22.8)	< 0.001
DLCO, percentage predicted value (%)	88 (42–142)	76 (43–118)	< 0.001
Regimen of concurrent chemotherapy
Carboplatin and paclitaxel	187 (70.8)	41 (77.4)	0.720
Docetaxel and cisplatin	68 (25.8)	11 (20.8)
Weekly cisplatin	3 (1.1)	0
Others	6 (2.3)	1 (1.9)
Radiation therapy technique
3D-CRT	134 (50.8)	18 (34.0)	0.037
VMAT	130 (49.2)	35 (66.0)
Consolidative durvalumab	20 (7.6)	3 (5.7)	0.841
EQD2 of prescribed dose (Gy)	60.0 (44.0–93.3)	60.0 (40.0–81.3)	0.054
Bilateral lung mean dose (Gy)	15.76 (4.33–24.05)	18.07 (4.78–22.75)	< 0.001
Bilateral lung V5 (%)	57.7 (16.7–96.6)	72.8 (27.9–100.0)	< 0.001
Bilateral lung V20 (%)	25.5 (5.8–44.1)	32.3 (4.7–41.5)	< 0.001
Bilateral lung volume (cm³)	3,183 (1,336–5,960)	2,876 (1,699–4,680)	0.196
Heart mean dose (Gy)	10.17 (0.0–39.63)	16.89 (0.10–41.23)	< 0.001
Size of PTV (cm³)	350 (63–1,188)	413 (137–1,324)	0.026
Duration of radiation therapy (day)	44 (16–88)	44 (20–56)	0.452

Table 2

Toxicity grading of symptomatic radiation pneumonitis and abnormal laboratory results

Grade	Symptomatic radiation pneumonitis	Pneumonia	Anemia	Leukopenia	Neutropenia	Lymphocytopenia	Thrombocytopenia	Hypoalbuminemia
1	-^a)	-^b)	215 (68.0)	90 (28.5)	37 (11.7)	5 (1.6)	78 (24.7)	33 (10.4)
2	63 (19.9)	13 (4.1)	77 (24.4)	107 (33.9)	59 (18.7)	48 (15.1)	10 (3.2)	32 (10.1)
3	10 (3.2)	16 (5.0)	0	56 (17.7)	35 (11.1)	179 (56.5)	5 (1.6)	2 (0.6)
4	3 (0.9)	4 (1.3)	0	7 (2.2)	4 (1.3)	82 (25.9)	1 (0.3)	0
5	9 (2.8)	10 (3.2)	0	-^b)	-^b)	-^b)	-^b)	0

Values are presented as number (%).

^a)Grade 1 radiation pneumonitis is asymptomatic,

^b)The event was not defined in Common Terminology Criteria for Adverse Events ver. 5.0.

Table 3

Univariate and multivariate analyses of the occurrence of post-chemoradiotherapy pulmonary complications

Characteristic (comparison vs. reference)	Univariate analysis			Multivariate analysis^a)
Characteristic (comparison vs. reference)	OR	95% CI	Adjusted p-value	OR	95% CI	p-value
Age at diagnosis (continuous, per a year)	1.050	1.015–1.088	0.019	1.007	0.959–1.056	0.790
Sex (female vs. male)	0.782	0.306–1.751	0.767	-	-	-
Amount of smoking (continuous, per pack-year)	1.013	1.001–1.026	0.083	1.010	0.992–1.028	0.248
Body mass index (continuous, per kg/m²)	0.985	0.893–1.083	0.834	-	-	-
Histology (others vs. adenocarcinoma)	1.156	0.639–2.123	0.771	-	-	-
FEV₁ (continuous, L)	0.660	0.401–1.061	0.162	-	-	-
FEV₁, percentage predicted value (continuous, per 10%)	0.999	0.862–1.160	0.994	-	-	-
FVC (continuous, per L)	0.628	0.415–0.936	0.062	0.741	0.398–1.346	0.333
FVC, percentage predicted value (continuous, per 10%)	0.916	0.757–1.110	0.545	-	-	-
FEV₁/FVC, percentage predicted value (continuous, per 10%)	1.075	0.821–1.427	0.769	-	-	-
DLCO (continuous, per mL/min/mmHg)	0.801	0.729–0.872	< 0.001	0.855	0.743–0.974	0.022
DLCO, percentage predicted value (continuous, per 10%)	0.662	0.544–0.793	< 0.001	-	-	-
Regimen of concurrent chemotherapy (others vs. carboplatin and paclitaxel)	0.711	0.341–1.388	0.523	-	-	-
Radiation therapy technique (3D-CRT vs. VMAT)	0.499	0.264–0.915	0.064	0.671	0.294–1.498	0.333
EQD2 of prescribed dose (continuous, per Gy)	0.942	0.885–0.999	0.098	0.949	0.874–1.021	0.184
Bilateral lung mean dose (continuous, per Gy)	1.178	1.081–1.293	0.001	-	-	-
Bilateral lung V5 (continuous, per 10%)	1.692	1.386–2.095	< 0.001	1.872	1.336–2.699	< 0.001
Bilateral lung V20 (continuous, per 10%)	2.358	1.548–3.705	0.001	-	-	-
Bilateral lung volume (continuous, per 100 cm³)	0.976	0.939–1.012	0.323	-	-	-
Heart mean dose (continuous, per Gy)	1.065	1.031–1.102	0.001	0.969	0.918–1.020	0.231
Size of PTV (continuous, per 100 cm³)	1.175	1.039–1.327	0.027	0.938	0.781–1.118	0.479
Duration of radiation therapy (continuous, per day)	0.981	0.934–1.030	0.630	-	-	-
Anemia grade ≥ 2 (yes vs. no)	3.084	1.645–5.754	0.001	1.357	0.575–3.135	0.478
Leukopenia grade ≥ 2 (yes vs. no)	1.002	0.552–1.830	0.994	-	-	-
Neutropenia grade ≥ 2 (yes vs. no)	1.097	0.570–2.047	0.834	-	-	-
Lymphocytopenia grade ≥ 3 (yes vs. no)	3.005	1.159–10.27	0.085	1.067	0.323–4.311	0.920
Thrombocytopenia grade ≥ 2 (yes vs. no)	0.714	0.110–2.663	0.773	-	-	-
Hypoalbuminemia grade ≥ 1 (yes vs. no)	7.186	3.806–13.77	< 0.001	5.670	2.487–13.40	< 0.001

^a)Multivariate analysis was performed with data from 239 patients, due to missing data in DLCO and albumin level.

Table 1 Patient characteristics and treatment details

Table 2 Toxicity grading of symptomatic radiation pneumonitis and abnormal laboratory results

Values are presented as number (%).

Grade 1 radiation pneumonitis is asymptomatic,

The event was not defined in Common Terminology Criteria for Adverse Events ver. 5.0.

Table 3 Univariate and multivariate analyses of the occurrence of post-chemoradiotherapy pulmonary complications

Multivariate analysis was performed with data from 239 patients, due to missing data in DLCO and albumin level.